| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:14599506 | IVR | 20 mg/kg | 20 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg | 20 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects peneration rate of sperms | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects peneration rate of sperms | Reproductive endocrine-mediated perturbations | |
| PMID:2106055 | IVR | 15 mg/kg | 15 mg/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations |
| IVR | 15 mg/kg | 15 mg/kg | Increased retinyl palmitate content | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Increased retinol content | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased retinol content | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Decreased retinol content | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased retinyl palmitate content | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| PMID:9284533 | IVR | 10 mg/L | 10 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/L | 10 mg/L | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/L | - | No significant effects observed | - | |
| IVR | 0.01 mg/L | - | No significant effects observed | - | |
| IVR | 1 mg/L | 1 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:9726532 | IVR | 0.1 mg/kg | 0.1 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects anogenital distance | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.